IGM Biosciences, Inc. - IGMS STOCK NEWS

IGM Biosciences reported its Q2 2021 financial results, revealing a net loss of $38.7 million, or $1.16 per share, compared to a loss of $18.8 million, or $0.62 per share in Q2 2020. Cash and investments totaled $301.8 million at the end of June 2021, a decline from $366.3 million at year-end 2020. The company is making progress in its pipeline, with ongoing trials for IGM-2323 and IGM-8444. Additionally, it plans to file an IND for IGM-7354 this year and expects to end 2021 with over $200 million in cash and investments.

IGM Biosciences (Nasdaq: IGMS) announced the appointment of Dr. Chris H. Takimoto as Chief Medical Officer, effective today. Dr. Takimoto brings over 30 years of oncology expertise, previously serving at Gilead Sciences. He will oversee IGM’s clinical pipeline of engineered IgM antibodies, following Dr. Daniel S. Chen's transition to a consulting role. CEO Fred Schwarzer praised Dr. Takimoto's extensive experience in clinical development. IGM aims to leverage its advanced IgM technology to enhance therapeutic applications across oncology and other fields.

IGM Biosciences announced plans to advance IGM-6268, the first intranasally administered IgM antibody, into clinical trials in Q3 2021. This new candidate targets COVID-19 and builds on findings published in Nature, highlighting its superior neutralization potency against SARS-CoV-2 variants compared to IgG antibodies. Preclinical studies indicate that IGM-6268 offers significant protective effects with a promising safety profile. The technology platform's expansion into infectious diseases marks a key development for IGM Biosciences in combating viral challenges.

IGM Biosciences, a clinical-stage biotechnology firm, announced that CEO Fred Schwarzer will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 1:00 p.m. EDT. A live webcast can be accessed via the company's 'Events and Presentations' page on its website, with a replay available for 90 days post-event. IGM focuses on developing engineered IgM antibodies for various diseases, aiming to overcome manufacturing challenges since 2010.

IGM Biosciences (Nasdaq: IGMS), a biotechnology company focused on engineered IgM antibodies, announced that CEO Fred Schwarzer will participate in a fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 1:55 p.m. EDT. The event will be held virtually. A live webcast will be accessible on the company’s website, with a replay available for 90 days post-event. This forum highlights IGM's progress since 2010 in overcoming challenges in IgM antibody development.

IGM Biosciences (Nasdaq: IGMS) reported Q1 2021 net loss of $31.6 million, up from $17.6 million in 2020. Cash and investments decreased to $331.7 million from $366.3 million in Q4 2020. The company anticipates a recommended Phase 2 dose for IGM-2323 and expects to report initial data from its Phase 1 trial of IGM-8444 later this year. IGM also plans to file an IND for IGM-7354. Despite rising R&D expenses ($23.6 million vs. $14.6 million), the company maintains a full-year operating expense guidance of $175-$185 million, with expected cash reserves over $200 million by year-end.

IGM Biosciences, a clinical-stage biotechnology firm, announced that CEO Fred Schwarzer will speak at the Truist Securities Life Sciences Summit on May 4, 2021, at 4:20 p.m. EDT. The summit will occur virtually, and interested parties can access a live webcast on the company’s website. A replay will be available for 90 days post-event. IGM Biosciences focuses on developing engineered IgM antibodies for treating various diseases, leveraging its proprietary technology platform to overcome challenges in IgM antibody production.

IGM Biosciences appointed George A. Gauthier as Chief Commercial Officer, leveraging 20 years of global life sciences experience. Previously at Genentech, Gauthier led strategies for breast and gynecological cancers. CEO Fred Schwarzer highlighted Gauthier's role in advancing the commercialization of IGM's engineered IgM antibodies. IGM focuses on overcoming the challenges in IgM antibody development, aiming to utilize their unique properties in therapeutic applications. The company continues its journey in clinical-stage biotechnology, committed to innovative patient treatments.

IGM Biosciences (Nasdaq: IGMS) reported its Q4 and full-year 2020 financial results on March 30, 2021. The company’s cash and investments increased to $366.3 million from $236.6 million a year prior. R&D expenses rose to $65.0 million from $35.3 million, and G&A expenses increased to $18.3 million from $9.2 million. The net loss for 2020 was $81.4 million, with a loss per share of $2.65. In terms of clinical development, IGM aims to establish a Phase 2 dose for IGM-2323 and file an IND for IGM-7354 in 2021. The company anticipates full-year operating expenses between $175 million and $185 million.